Company announcement no. 1-2019
Birkerød, 6 March 2019
ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for emergency departments in hospitals, today announces that it has completed the development and regulatory approval of its suPARnostic® TurbiLatex product for Roche Diagnostics cobas c 502, which is one of the most used clinical chemistry modules for photometric assay tests, such as suPAR, in large, central hospital laboratories across Europe.
ViroGates’ suPARnostic® TurbiLatex product was initially developed and approved for the Roche Diagnostics cobas C 111 analyzer. In line with previous disclosure from ViroGates, the company has now also validated suPARnostic® TurbiLatex for the cobas c 502 module. According to an internal report, more than 15,000 cobas instruments are installed worldwide.
suPARnostic® TurbiLatex enables automatic handling of blood samples at clinical chemistry laboratories, such as central hospital laboratories, and is thus a pivotal element in the company’s European expansion strategy with special focus on the acute care market.
CEO Jakob Knudsen, says in a comment: ”We are really excited to launch this new application of our suPARnostic® TurbiLatex product line. Cobas c 502 is what many hospitals rely on in daily clinical routine testing. This means, that hospitals can now run suPARnostic® on their standard instruments with no additional hands on work or procedures, and test results are reported to the emergency departments in the same manner as other blood parameters. We believe, that this will significantly strengthen our sales efforts.”
About the turbidimetric measurement principle: The TurbiLatex product is based on a technology called turbidimetry that measures the loss of intensity of transmitted light due to the scattering effect of particles suspended in the blood sample. The principle of measuring blood samples by using turbidimetry is very important in relation to immunoassays, as it is the basis for almost all central laboratory clinical chemistry instrument platforms in hospitals.
For further information contact:
CEO Jakob Knudsen
Tel. (+45) 2113 1336, Email: jk@virogates.com
ViroGates A/S
CVR-nr. 25734033, Blokken 45, DK-340 Birkerød
www.virogates.com
Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se
About ViroGates
ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage and TurbiLatex test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 550 clinical trials and studies which included more than 300,000 blood samples.
Attachment
